McKesson Agrees To Buy Vantage Oncology And Biologics In Two Deals Worth $1.2 Billion

McKesson Corp. said Thursday it has agreed to acquire Vantage Oncology LLC and Biologics Inc. in two transactions valued at $1.2 billion. McKesson said it will fund the deals with a mix of cash and debt and expects it to close in the first quarter of fiscal 2017. The deals will boost McKesson's specialty pharmaceuticals distribution and oncology-based offerings." We will also be able to offer additional value-added services to our manufacturer partners, expand our reach and pharmaceutical distribution scale, and provide care management and care coordination for payers as the industry moves towards value-based reimbursement models," Chief Executive John Hammergren said in a statement. The company is expecting the deal to add 11 cents to fiscal 2017 adjusted per-share earnings. McKesson shares rose 3.5% in premarket trade, but are down 33% in the last 12 months, while the S&P 500 has fallen 9%.